NZ734670A - Cells for producing recombinant iduronate-2-sulfatase - Google Patents

Cells for producing recombinant iduronate-2-sulfatase

Info

Publication number
NZ734670A
NZ734670A NZ734670A NZ73467013A NZ734670A NZ 734670 A NZ734670 A NZ 734670A NZ 734670 A NZ734670 A NZ 734670A NZ 73467013 A NZ73467013 A NZ 73467013A NZ 734670 A NZ734670 A NZ 734670A
Authority
NZ
New Zealand
Prior art keywords
recombinant
cells
protein
sulfatase
cell
Prior art date
Application number
NZ734670A
Other languages
English (en)
Inventor
Ferenc Boldog
Michael Heartlein
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of NZ734670A publication Critical patent/NZ734670A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/99Oxidoreductases acting on sulfur groups as donors (1.8) with other acceptors (1.8.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/10Plasmid DNA
    • C12N2800/106Plasmid DNA for vertebrates
    • C12N2800/107Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NZ734670A 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase NZ734670A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666719P 2012-06-29 2012-06-29
NZ703137A NZ703137A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Publications (1)

Publication Number Publication Date
NZ734670A true NZ734670A (en) 2019-12-20

Family

ID=49778522

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ734670A NZ734670A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase
NZ703137A NZ703137A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ703137A NZ703137A (en) 2012-06-29 2013-06-28 Cells for producing recombinant iduronate-2-sulfatase

Country Status (27)

Country Link
US (3) US9150841B2 (https=)
EP (1) EP2874649B1 (https=)
JP (3) JP6067849B2 (https=)
KR (1) KR101710487B1 (https=)
CN (2) CN107267460A (https=)
AU (3) AU2013282400B2 (https=)
BR (1) BR112014032560B1 (https=)
CA (1) CA2877521C (https=)
CL (1) CL2014003568A1 (https=)
CO (1) CO7240394A2 (https=)
CR (1) CR20140586A (https=)
DO (1) DOP2014000298A (https=)
EA (2) EA202090805A1 (https=)
ES (1) ES2718346T3 (https=)
GT (1) GT201400302A (https=)
HK (1) HK1209331A1 (https=)
IL (3) IL236343A (https=)
MX (2) MX336716B (https=)
MY (2) MY189314A (https=)
NZ (2) NZ734670A (https=)
PE (1) PE20150957A1 (https=)
PH (2) PH12016500011B1 (https=)
SG (2) SG11201408702VA (https=)
TR (1) TR201904435T4 (https=)
UA (1) UA118955C2 (https=)
WO (1) WO2014005019A2 (https=)
ZA (1) ZA201409396B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6473079B2 (ja) * 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現
US20140004097A1 (en) * 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US9550972B2 (en) 2014-09-29 2017-01-24 General Electric Company Devices, systems and methods for automated cell culturing
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
CR20200129A (es) 2017-10-02 2020-08-22 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas de terapia de reemplazo de enzimas
JP7060235B2 (ja) * 2018-05-18 2022-04-26 国立大学法人広島大学 変異型イズロン酸-2-スルファターゼの機能回復薬剤のスクリーニング方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
WO1995024920A1 (en) 1994-03-16 1995-09-21 The Regents Of The University Of California Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
AU4330597A (en) 1996-08-30 1998-03-19 Life Technologies, Inc. Serum-free mammalian cell culture medium, and uses thereof
WO2001018022A1 (en) 1999-09-03 2001-03-15 Human Genome Sciences, Inc. 52 human secreted proteins
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
CA2645739A1 (en) 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
CA2711590C (en) 2008-01-18 2021-03-23 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CN102665890B (zh) * 2009-10-09 2016-02-24 蓝立方知识产权公司 生产氯化和/或氟化丙烯和高级烯烃的绝热活塞流反应器及方法
EP2485761B1 (en) 2009-10-09 2019-02-27 Armagen, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
WO2011108451A1 (ja) 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
KR20230159646A (ko) 2010-06-25 2023-11-21 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase

Also Published As

Publication number Publication date
GT201400302A (es) 2019-05-22
TR201904435T4 (tr) 2019-05-21
PH12016500011A1 (en) 2019-08-14
IL274266A (en) 2020-06-30
UA118955C2 (uk) 2019-04-10
EA201492183A1 (ru) 2015-06-30
IL236343A0 (en) 2015-02-26
WO2014005019A3 (en) 2014-02-27
EA035511B1 (ru) 2020-06-26
MY157086A (en) 2016-04-19
SG11201408702VA (en) 2015-02-27
JP6302499B2 (ja) 2018-03-28
EA202090805A1 (ru) 2020-11-30
EP2874649A2 (en) 2015-05-27
EP2874649B1 (en) 2019-01-02
MX336716B (es) 2016-01-28
ZA201409396B (en) 2018-05-30
HK1209331A1 (en) 2016-04-01
US20180010108A1 (en) 2018-01-11
EP2874649A4 (en) 2016-05-04
CO7240394A2 (es) 2015-04-17
US20140004593A1 (en) 2014-01-02
MY189314A (en) 2022-02-04
CR20140586A (es) 2015-04-06
BR112014032560A2 (pt) 2018-03-06
CA2877521C (en) 2021-06-01
CA2877521A1 (en) 2014-01-03
AU2018200710A1 (en) 2018-02-22
PH12014502868B1 (en) 2015-02-23
BR112014032560B1 (pt) 2022-04-26
AU2016200460B2 (en) 2017-11-02
JP2015521848A (ja) 2015-08-03
CN107267460A (zh) 2017-10-20
HK1209651A1 (en) 2016-04-08
KR20150030242A (ko) 2015-03-19
US9150841B2 (en) 2015-10-06
WO2014005019A2 (en) 2014-01-03
JP6067849B2 (ja) 2017-01-25
CL2014003568A1 (es) 2015-04-24
US9719074B2 (en) 2017-08-01
AU2013282400A1 (en) 2015-01-29
AU2016200460A1 (en) 2016-02-18
US20160053238A1 (en) 2016-02-25
KR101710487B1 (ko) 2017-02-27
PH12014502868A1 (en) 2015-02-23
ES2718346T3 (es) 2019-07-01
DOP2014000298A (es) 2015-03-31
IL254560A0 (en) 2017-11-30
JP6755272B2 (ja) 2020-09-16
AU2013282400B2 (en) 2016-02-04
JP2016105737A (ja) 2016-06-16
SG10201509397SA (en) 2015-12-30
IL254560B (en) 2020-05-31
PE20150957A1 (es) 2015-07-15
MX2015000189A (es) 2015-04-08
PH12016500011B1 (en) 2022-07-15
NZ703137A (en) 2017-08-25
JP2018088933A (ja) 2018-06-14
IL274266B (en) 2021-04-29
CN104540517A (zh) 2015-04-22
MX366155B (es) 2019-06-28
AU2018200710B2 (en) 2019-11-14
IL236343A (en) 2017-10-31

Similar Documents

Publication Publication Date Title
NZ703137A (en) Cells for producing recombinant iduronate-2-sulfatase
MY156588A (en) Systems using cell culture for production of isoprene
AU2018271755A1 (en) Method for culturing natural killer cell, using transformed T cell
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
SG10201810830UA (en) Cell culture compositions and methods for polypeptide production
MX339769B (es) Sistemas, metodos y composiciones para optimizar injertos enriquecidos con celulas y tejidos.
MX2024012982A (es) Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t
MX348696B (es) Procesos para la produccion de productos de fermentacion.
SG10201809901SA (en) Generating Pluripotent Cells De Novo
MX2015000188A (es) Metodo para producir iduronato-2-sulfatasa recombinante.
MX2011013700A (es) Cepa talaromyces y composiciones de enzimas.
MX2014009306A (es) Metodo sin alimentadoras para cultivo de celulas madre espermatogonias de bovino y porcino.
EP2633036A4 (en) DIFFERENTIATION METHOD FOR THE PRODUCTION OF GLIA CELL POPULATIONS
MX355785B (es) Composicions y metodos para la biosintesis de vainillina o de beta-d-glucosido de vainillina.
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX369395B (es) Modulacion del crecimiento celular y glucosilacion en la produccion de glucoproteina recombinante.
MX2021009554A (es) Produccion de virus en cultivos celulares.
GB201203085D0 (en) Hydrogels
SG10201901559SA (en) Retinal ganglion cells and progenitors thereof
MY182946A (en) Production of organic acids by fermentation at low ph
WO2012074265A3 (ko) 줄기세포의 안정성 증진용 조성물
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
MY161163A (en) Culture medium for human mesenchymal stem cells
MX2024014098A (es) Fabricacion de particulas virales
IL231490B (en) A viral vector containing a plant DNA sequence (codon-optimized) and a method for the temporary production of cholinesterase using this vector

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2021 BY ANAQUA SERVICES

Effective date: 20200520

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2022 BY ANAQUA SERVICES

Effective date: 20210519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2023 BY ANAQUA SERVICES

Effective date: 20220523

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2024 BY ANAQUA SERVICES

Effective date: 20230524

ASS Change of ownership

Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP

Effective date: 20231115

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2025 BY ANAQUA SERVICES

Effective date: 20240521

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 28 JUN 2026 BY ANAQUA SERVICES

Effective date: 20250521